Abstract
Renal amyloid involvement results, especially, from AL (primary) or AA (secondary) amyloidosis. The extent of amyloid tissue deposits in the kidneys and the clinical course of amyloidosis not only depend on the type of basic process but also reflect the time of diagnosis and the ability to affect the underlying disease. We analyzed laboratory and clinical data from patients with bioptically proven renal amyloidosis. Renal amyloidosis was found in 99 patients (4.65%) from an overall number of 2,128 renal biopsies (RB) performed in our department during a period of 11 years (from 1995 to 2006). AA amyloidosis was diagnosed in 46 patients. Nephrotic syndrome was diagnosed in 27 patients (59%) with AA amyloidosis; all these patients had different degrees of proteinuria. Impaired renal function was discovered in 24 patients (52%); in three of these patients (6.5%) we had to start renal replacement therapy. Patients were treated with corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biological therapy in various regimens. Nine patients (19.5%) died during the one-year follow-up period; complications such as sepsis and cardiac failure were the leading causes of death. Median survival in the AA group was 54 months. Although for approximately half of patients different treatment regimens can lead to a partial remission or disease stabilization, the prognosis of patients with amyloidosis could be regarded as unsatisfactory.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Obici L, Perfetti V, Palladii G, Moratti R, Merlini G (2005) Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta (BBA)—Proteins Proteomics 1753(1):11–22. doi:10.1016/j.bbapap.2005.08.014
Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 70:246–256. doi:10.1097/00005792-199107000-00002
Hazenberg BP, van Rijswijk MH (1994) Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 8:661–690. doi:10.1016/S0950-3579(05)80121-9
Grateau G (2004) Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology 43:410–415. doi:10.1093/rheumatology/keh157
Obici L, Manno C, Onetti Muda A, Picco P, D’Osualdo A, Paladini G, Avanzini MA, Torres D, Marciano S, Merlini G (2004) First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 50:2966–2969. doi:10.1002/art.20490
Rocken C, Shakespeare A (2002) Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440:111–122. doi:10.1007/s00428-001-0582-9
Yamada T (1999) Serum amyloid A (SAA). A concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37:381–388. doi:10.1515/CCLM.1999.063
Ancsin JB, Kisilevsky R (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 274:7172–7181. doi:10.1074/jbc.274.11.7172
Elimova E, Kisilevsky R, Szarek WA, Ancsin JB (2004) Amyloidogenesis recapitulated in cell culture. A peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 18:1749–1751
Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 102:6473–6477. doi:10.1073/pnas.0502287102
Hawkins PN (2002) Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 11:649–655. doi:10.1097/00041552-200211000-00013
Demircin G, Delibaş A, Bek K et al (2008) A one-center experience with pediatric percutaneous renal biopsy and histopathology in Ankara, Turkey. Int Urol Nephrol. doi:10.1007/s11255-008-9433-9
Joss N, McLaughlin K, Simpson K, Boulton-Jones JM (2000) Presentation, survival and prognostic markers in AA amyloidosis. Q J Med 93:535–542
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Salomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 79:319–328. doi:10.1002/ajh.20381
Rychlik I, Jancova E, Tesar V et al (2004) The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994–2000. Nephrol Dial Transplant 19:3040–3049. doi:10.1093/ndt/gfh521
Kaipiainen-Sepannen O, Aho K, Isomaki H, Laakso M (1996) Shift in the incidence of rheumatoid arthritis towards elderly patients in Finland during 1875–1990. Clin Exp Rheumatol 14:537–542
Hazenberg BPC, van Rijswijk MH (2000) Where has secondary amyloidosis gone? Ann Rheum Dis 59:577–579. doi:10.1136/ard.59.8.577
Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, Salvadori M (2007) Renal involvement in systemic amyloidosis-an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant 22:1608–1618. doi:10.1093/ndt/gfm041
Immonen K, Finne P, Hakala M, Kautiainen H, Pettersson T, Grönhagen-Riska C (2008) No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases—Data from the Finnish national registry for kidney diseases. J Rheumatol 35:7
Rysava R, Merta M, Spicka I, Tesar V (2003) Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients. Nephrol Dial Transplant 18(5):38–40. doi:10.1093/ndt/gfg1043
Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24–29. doi:10.1016/S0140-6736(00)05252-1
Acknowledgement
This work was supported by the Czech Registry of Renal Biopsy, by the grant of Czech Society of Nephrology 2008/02, and by the research project MZO 00023728.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Potyšová, Z., Merta, M., Tesař, V. et al. Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre. Int Urol Nephrol 41, 941–945 (2009). https://doi.org/10.1007/s11255-009-9524-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-009-9524-2